Skip to content
drillr.ai
Sign up

SYRE

Spyre Therapeutics, Inc.

NASDAQ · Healthcare · Biotechnology · US

$84.72
+6.03%
Ask drillr

  • Oct 18, 2026, 13:30 UTC

    Spyre Therapeutics, Inc. announced that it will present clinical and preclinical data at United European Gastroenterology Week 2026 in Barcelona.

    Source:

  • Oct 6, 2026, 15:33 UTC

    Spyre Therapeutics announced a common stock offering of 4.12 million shares at $85 per share, a 8.33% discount to the prior close, to raise about $350 million.

    Source:

  • Oct 5, 2026, 20:01 UTC

    Spyre Therapeutics, Inc. commenced an underwritten public offering of its common stock, with an expected 30-day underwriters' option for an additional 15% of the shares offered.

    Source:

  • Oct 2, 2026, 20:05 UTC

    Spyre Therapeutics granted stock options for 21,424 shares and 6,604 restricted stock units to two non-executive employees as equity inducement awards under its 2018 Equity Inducement Plan.

    Source:

  • Aug 26, 2026, 12:22 UTC

    Spyre Therapeutics shares fell 12.35% in after-hours trading after its mid-stage clinical trial for a rheumatoid arthritis drug failed to meet internal criteria for advancing as a monotherapy.

    Source:

  • Aug 7, 2026, 20:05 UTC

    Spyre Therapeutics' Compensation Committee approved equity inducement awards of stock options for 19,436 shares and 6,186 restricted stock units to four non-executive employees on August 3, 2026, as material inducements to their employment acceptance.

    Source:

  • Aug 5, 2026, 16:11 UTC

    Spyre reported its Q2 2026 financial results, with a narrower-than-expected loss.

    Source:

  • Aug 4, 2026, 20:02 UTC

    Spyre Therapeutics announced positive topline induction data for SPY001 and SPY002 from Part A of the Phase 2 SKYLINE trial, demonstrating best-in-class efficacy potential and a safety profile consistent with in-class comparators.

    Source:

  • Jul 2, 2026, 20:05 UTC

    Spyre Therapeutics granted stock options and restricted stock units to six non-executive employees as inducement awards to accept employment.

    Source:

  • Jun 15, 2026, 12:28 UTC

    Spyre Therapeutics announced that its experimental bowel disease drug met the main goal of significantly reducing disease severity in a mid-stage trial.

    Source:

  • Jun 3, 2026, 12:00 UTC

    Spyre Therapeutics completed enrollment in the SKYWAY basket trial evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA.

    Source: